All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | MicrobiomeTrials
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2022-02-10Est. Completion: 2024-05-27
Enrollment target: 21 participants
Locations
GSK Investigational Site, Nagoya, Aichi-ken, Japan
GSK Investigational Site, Kamogawa, Chiba, Japan
GSK Investigational Site, Kashiwa, Chiba, Japan
GSK Investigational Site, Matsuyama, Ehime, Japan
GSK Investigation Site, Fukushima, Fukushima, Japan
GSK Investigational Site, Maebashi, Gunma, Japan
GSK Investigational Site, Shibukawa, Gunma, Japan
GSK Investigational Site, Numakunai, Iwate, Japan
GSK Investigational Site, Okayama, Okayama-ken, Japan
GSK Investigational Site, Osaka, Osaka, Japan
GSK Investigational Site, Tottori-shi, Tottori, Japan
GSK Investigational Site, Yamagata, Yamagata, Japan
GSK Investigational Site, Hokkaido, Japan
Other microbiome trials you might be interested in